It bypasses some of those metabolic blocks like folate receptor antibodies that I've mentioned at the beginning of this episode
The rapid rise of GLP-1 receptor agonists like semaglutide and tirzepatide has transformed obesity and diabetes care, generating billions in revenue for manufacturers Novo Nordisk and Eli Lilly, while creating unprecedented demand for weight management solutions
Helios is their combination of Clenbuterol and Yohimbe, which I can only imagine being a pretty strong fat burner
Provider continuity - Will you see the same prescriber for follow-ups, or different providers each time
Alternative mitochondrial quality control mediated by extracellular release
While there are limitations, the promise of improved diabetes management, cardiovascular benefits, and new formulations places GLP-1 agonists at the forefront of diabetes care